Anzeige
Mehr »
Login
Dienstag, 23.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Der KI-Boom ist vorbei! Aber dieser heiße Sektor verspricht, weiter zu wachsen...
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DU45 | ISIN: US23666P1012 | Ticker-Symbol: 1221
Tradegate
22.04.24
20:35 Uhr
0,279 Euro
-0,001
-0,18 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
DARE BIOSCIENCE INC Chart 1 Jahr
5-Tage-Chart
DARE BIOSCIENCE INC 5-Tage-Chart
RealtimeGeldBriefZeit
0,2760,28322.04.

Aktuelle News zur DARE BIOSCIENCE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
11.04.Daré Bioscience, Inc.: Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene: an Investigational Hormone-Free Monthly Intravaginal Contraceptive129Published data shows that Ovaprene was safe and effective in a postcoital test study of 33 women Pivotal Phase 3 contraceptive efficacy clinical study of Ovaprene currently enrolling Ovaprene has...
► Artikel lesen
01.04.Daré Bioscience, Inc. (DARE) Q4 2023 Earnings Call Transcript4
01.04.Earnings call: Daré Bioscience reports Q4 results, advances in women's health4
28.03.Recap: Dare Bioscience Q4 Earnings2
28.03.Dare Bioscience Inc reports results for the quarter ended in December - Earnings Summary2
28.03.Dare Bioscience GAAP EPS of -$0.35 beats by $0.02, revenue of $2.81M beats by $0.69M4
28.03.Dare Bioscience, Inc. - 8-K, Current Report-
28.03.Daré Bioscience, Inc.: Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update2992023 Highlights and Anticipated 2024 Milestones XACIATO (clindamycin phosphate) vaginal gel 2% is available by prescription in the United States to treat bacterial vaginosis under license agreement...
► Artikel lesen
27.03.Dare Bioscience Earnings Preview4
21.03.Daré Bioscience, Inc.: Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 20245
31.01.Daré Bioscience, Inc.: Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024221SAN DIEGO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Dare´ Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, and its collaborator Strategic Science & Technologies, LLC (SST), a Cambridge...
► Artikel lesen
26.01.Daré Bioscience, Inc.: Daré Bioscience Announces Executive Team and Board of Directors Changes320SAN DIEGO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Dare´ Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced changes in company management which includes the retirement...
► Artikel lesen
19.01.Dare Bioscience, Inc. - 8-K, Current Report5
17.01.Daré Bioscience, Inc.: Daré Bioscience Announces Grant to Support Biotherapeutic Product Development619SAN DIEGO, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced it has received a grant from the Bill & Melinda Gates Foundation...
► Artikel lesen
08.01.Dare Bioscience, Inc. - 8-K, Current Report4
04.01.Daré Bioscience, Inc.: Daré Bioscience's DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women's Health as well as in Treating a Broad Range of Diseases222SAN DIEGO, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Dare´ Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that it has achieved technological proof of concept for DARE-LARC1...
► Artikel lesen
26.12.23Dare Bioscience secures $12M in royalty-backed investment structure7
26.12.23Daré Bioscience, Inc.: Daré Bioscience Secures $12 million in Royalty-backed Investment Structure5
20.12.23Daré Bioscience, Inc.: Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study210SAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Dare´ Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced positive topline results from the Phase 1 study evaluating...
► Artikel lesen
20.12.23Dare Bioscience, Inc. - 8-K, Current Report1
Seite:  Weiter >>
34 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1